GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Market Cap	11.19B
Revenue (ttm)	211.98M +42.0%
Net Income	-1.02B
EPS	-38.59
Shares Out	370.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	760,008
Average Volume	701,983
Open	29.80
Previous Close	31.14
Day's Range	29.12 - 31.10
52-Week Range	19.60 - 50.20
Beta	n/a
RSI	50.38
Earnings Date	n/a

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 94
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2595

Financial Performance

Financial numbers in CNY